Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

JNJ-61186372 demonstrates activity for the treatment EGFR/c-Met-aberrant malignancies

April 8, 2014

IGM-55.5 potently binds and kills B cells in NHL patients

April 8, 2014

Clinical study evaluates immunological response EMD-640744 in solid tumors

April 8, 2014

New START2 trial investigates tecemotide in stage III NSCLC

April 7, 2014

MT-3724 shows significant antitumor activity in vitro and in vivo

April 7, 2014

Amgen reports topline results from phase III study of talimogene laherparepvec

April 7, 2014

GSK ends MAGRIT study of MAGE-A3 cancer immunotherapeutic

April 2, 2014

RG-7813 enters first clinical trial for cancer

March 31, 2014

Subcutaneous MabThera approved in Europe for two forms of NHL

March 31, 2014

Genmab achieves second milestone in daratumumab collaboration with Janssen

March 28, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
2026 marks critical turning point for BCI technology
BioWorld
Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...